Literature DB >> 9777854

Escherichia coli O157:H7.

P S Mead1, P M Griffin.   

Abstract

Escherichia coli O157 was first identified as a human pathogen in 1982. One of several Shiga toxin-producing serotypes known to cause human illness, the organism probably evolved through horizontal acquisition of genes for Shiga toxins and other virulence factors. E. coli O157 is found regularly in the faeces of healthy cattle, and is transmitted to humans through contaminated food, water, and direct contact with infected people or animals. Human infection is associated with a wide range of clinical illness, including asymptomatic shedding, non-bloody diarrhoea, haemorrhagic colitis, haemolytic uraemic syndrome, and death. Since laboratory practices vary, physicians need to know whether laboratories in their area routinely test for E. coli O157 in stool specimens. Treatment with antimicrobial agents remains controversial: some studies suggest that treatment may precipitate haemolytic uraemic syndrome, and other studies suggest no effect or even a protective effect. Physicians can help to prevent E. coli O157 infections by counselling patients about the hazards of consuming undercooked ground meat or unpasteurised milk products and juices, and about the importance of handwashing to prevent the spread of diarrhoeal illness, and by informing public-health authorities when they see unusual numbers of cases of bloody diarrhoea or haemolytic uraemic syndrome.

Entities:  

Mesh:

Year:  1998        PMID: 9777854     DOI: 10.1016/S0140-6736(98)01267-7

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  151 in total

1.  Rapid detection of enterohemorrhagic Escherichia coli by real-time PCR with fluorescent hybridization probes.

Authors:  T Bellin; M Pulz; A Matussek; H G Hempen; F Gunzer
Journal:  J Clin Microbiol       Date:  2001-01       Impact factor: 5.948

2.  Phage types and genotypes of Shiga toxin-Producing Escherichia coli O157 in Finland.

Authors:  M Saari; T Cheasty; K Leino; A Siitonen
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

Review 3.  Sorbitol-fermenting Shiga toxin-producing Escherichia coli O157:H(-) strains: epidemiology, phenotypic and molecular characteristics, and microbiological diagnosis.

Authors:  H Karch; M Bielaszewska
Journal:  J Clin Microbiol       Date:  2001-06       Impact factor: 5.948

4.  Genomic diversity of enterohemorrhagic Escherichia coli O157 revealed by whole genome PCR scanning.

Authors:  Makoto Ohnishi; Jun Terajima; Ken Kurokawa; Keisuke Nakayama; Takahiro Murata; Kazumichi Tamura; Yoshitoshi Ogura; Haruo Watanabe; Tetsuya Hayashi
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-12       Impact factor: 11.205

5.  Bacterial Infections of the Colon.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-06

Review 6.  Phages and the evolution of bacterial pathogens: from genomic rearrangements to lysogenic conversion.

Authors:  Harald Brüssow; Carlos Canchaya; Wolf-Dietrich Hardt
Journal:  Microbiol Mol Biol Rev       Date:  2004-09       Impact factor: 11.056

7.  Evaluation of the anti-terminator Q933 gene as a marker for Escherichia coli O157:H7 with high Shiga toxin production.

Authors:  Aqeel Ahmad; Ludek Zurek
Journal:  Curr Microbiol       Date:  2006-09-12       Impact factor: 2.188

Review 8.  Hemolytic uremic syndrome.

Authors:  Caterina Mele; Giuseppe Remuzzi; Marina Noris
Journal:  Semin Immunopathol       Date:  2014-02-14       Impact factor: 9.623

9.  Effect of long-term starvation on the survival, recovery, and carbon utilization profiles of a bovine Escherichia coli O157:H7 isolate from New Zealand.

Authors:  Ron N Xavier; Hugh W Morgan; Ian R McDonald; Helen Withers
Journal:  Appl Environ Microbiol       Date:  2014-05-09       Impact factor: 4.792

10.  Pathogenic potential of emergent sorbitol-fermenting Escherichia coli O157:NM.

Authors:  Tracy Rosser; Tracy Dransfield; Lesley Allison; Mary Hanson; Nicola Holden; Judith Evans; Stuart Naylor; Roberto La Ragione; J Christopher Low; David L Gally
Journal:  Infect Immun       Date:  2008-10-13       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.